drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy; CAR-engineered NK cells)
drug_description
Gene-modified, off-the-shelf allogeneic NK-92 cell therapy expressing an NKG2D chimeric antigen receptor that binds stress-induced ligands (e.g., MICA/MICB) on tumor cells to trigger NK-cell cytotoxicity (perforin/granzyme release and cytokine secretion).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Killer Cells, Natural
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic NK-92 cells engineered to express an NKG2D-based chimeric antigen receptor that binds stress-induced NKG2D ligands (e.g., MICA/MICB/ULBPs) on tumor cells, triggering NK-cell activation and CAR signaling to drive perforin/granzyme-mediated cytotoxicity and cytokine secretion, resulting in tumor cell lysis.
drug_name
NKG2D-CAR-NK92 cells
nct_id_drug_ref
NCT05528341